Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway

Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway

Almonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC). However, the development of resistance inevitably occ...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Chen Shi, Cong Wang, Zhiwen Fu, Jinmei Liu, Yuanfeng Zhou, Bao Cheng, Cong Zhang, Shijun Li, Yu Zhang
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: Elsevier 2024-03-01
Seri Bilgileri:Pharmacological Research
Konular:
LCN2
MMP-9
Pyroptosis
Almonertinib
Resistance
Online Erişim:http://www.sciencedirect.com/science/article/pii/S104366182400032X

Internet

http://www.sciencedirect.com/science/article/pii/S104366182400032X

Benzer Materyaller